<DOC>
	<DOCNO>NCT01665430</DOCNO>
	<brief_summary>This multicenter , open-label , single arm long term extension study WA19926 evaluate safety efficacy RoActemra/Actemra ( tocilizumab ) patient early , moderate severe rheumatoid arthritis complete WA19926 core study . Eligible patient receive RoActemra/Actemra 8 mg/kg intravenously every 4 week 104 week .</brief_summary>
	<brief_title>A Long-Term Extension Study WA19926 RoActemra/Actemra ( Tocilizumab ) Patients With Early , Moderate Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Patients complete WA19926 core study ( visit Week 104 two followup telephone visit ) may benefit study drug treatment accord Investigator 's assessment No current recent adverse event laboratory find prevent use study drug dose RoActemra/Actemra 8 mg/kg baseline visit Receiving treatment outpatient basis Females childbearing potential must agree use least one adequate method contraception define protocol treatment period Pregnant woman Patients prematurely withdraw WA19926 study reason Treatment investigational agent cell deplete therapy since last administration study drug WA 19926 core study Treatment antitumor necrosis factor ( TNF ) antiinterleukin ( IL ) 1 agent , Tcell costimulation modulator since last administration study drug WA19926 core study Immunization live/attenuated vaccine since last administration study drug WA19926 core study Diagnosis since visit Week 104 core WA19926 study rheumatic autoimmune disease rheumatoid arthritis Diagnosis since visit Week 104 core WA19926 study inflammatory joint disease rheumatoid arthritis Evidence serious uncontrolled concomitant disease disorder Known active history recurrent infection Current liver disease determine Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>